Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

about

The Clinical and Economic Burden of Hyperkalemia on Medicare and Commercial Payers.Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate Acute Hypocalcemia and Metabolic Alkalosis in Children on Cation-Exchange Resin Therapy

P2860

Q38631428-3D3A0F18-6363-4AF3-B50D-E6409B089A90 Q41355707-EBFBBF9A-6F1B-4BC0-9B01-36601E74BD6F Q41670957-DB97CCFD-AD5D-4087-9E2E-F0EA849FC5BE

P2860

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

Item

http://www.wikidata.org/entity/Q36425315

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

@ast

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

@en

type

Item

label

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

@ast

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

@en

prefLabel

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

@ast

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

@en

P1476

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

@en

P2093

Deepali Dixit

http://www.w3.org/2001/XMLSchema#string

Martin Chaitman

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions for non-oliguric hyperkalaemia in preterm neonates

Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?

Characterization of structure and function of ZS-9, a K+ selective ion trap

PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.

Effect of three laxatives and a cation exchange resin on fecal sodium and potassium excretion.

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Hyperkalemia: a review.

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.

Sodium zirconium cyclosilicate in hyperkalemia.

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.

P304

43-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mary Bridgeman

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26765867

http://www.w3.org/2001/XMLSchema#string

P932

4699486

http://www.w3.org/2001/XMLSchema#string

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

about

P2860

P2860

Potassium-Binding Agents for the Clinical Management of Hyperkalemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P50

P577

P698

P932